AbCellera Biologics (ABCL) Enterprise Value (2020 - 2025)
AbCellera Biologics' Enterprise Value history spans 6 years, with the latest figure at -$108.2 million for Q3 2025.
- For the quarter ending Q3 2025, Enterprise Value rose 28.67% year-over-year to -$108.2 million, compared with a TTM value of -$108.2 million through Sep 2025, up 28.67%, and an annual FY2024 reading of -$181.3 million, down 14.53% over the prior year.
- Enterprise Value for Q3 2025 was -$108.2 million at AbCellera Biologics, up from -$117.4 million in the prior quarter.
- The five-year high for Enterprise Value was -$108.2 million in Q3 2025, with the low at -$815.6 million in Q2 2022.
- Average Enterprise Value over 5 years is -$423.8 million, with a median of -$372.0 million recorded in 2022.
- Year-over-year, Enterprise Value tumbled 39.33% in 2023 and then skyrocketed 83.11% in 2025.
- Tracing ABCL's Enterprise Value over 5 years: stood at -$501.1 million in 2021, then surged by 43.07% to -$285.3 million in 2022, then skyrocketed by 44.51% to -$158.3 million in 2023, then decreased by 14.53% to -$181.3 million in 2024, then soared by 40.35% to -$108.2 million in 2025.
- Per Business Quant, the three most recent readings for ABCL's Enterprise Value are -$108.2 million (Q3 2025), -$117.4 million (Q2 2025), and -$184.3 million (Q1 2025).